ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 277 filers reported holding ROYALTY PHARMA PLC in Q1 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $85,002 | -16.4% | 3,132 | -5.3% | 0.00% | 0.0% |
| Q2 2023 | $101,719 | -24.6% | 3,309 | -11.6% | 0.00% | 0.0% |
| Q1 2023 | $134,860 | -10.8% | 3,743 | -2.2% | 0.00% | 0.0% |
| Q4 2022 | $151,204 | -2.4% | 3,826 | -0.6% | 0.00% | 0.0% |
| Q3 2022 | $155,000 | -3.7% | 3,851 | +0.3% | 0.00% | 0.0% |
| Q2 2022 | $161,000 | -18.3% | 3,841 | -23.9% | 0.00% | 0.0% |
| Q1 2022 | $197,000 | -2.5% | 5,044 | -0.7% | 0.00% | 0.0% |
| Q4 2021 | $202,000 | +6.3% | 5,080 | -3.4% | 0.00% | 0.0% |
| Q3 2021 | $190,000 | -19.1% | 5,259 | -8.2% | 0.00% | 0.0% |
| Q2 2021 | $235,000 | +2.2% | 5,727 | +8.7% | 0.00% | 0.0% |
| Q1 2021 | $230,000 | +132.3% | 5,270 | +166.8% | 0.00% | – |
| Q4 2020 | $99,000 | +47.8% | 1,975 | +24.4% | 0.00% | – |
| Q3 2020 | $67,000 | – | 1,587 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $106,824,000 | 67.12% |
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $269,465,000 | 56.37% |
| Vantage Consulting Group Inc | 4,601,152 | $183,355,000 | 49.30% |
| Indie Asset Partners, LLC | 805,982 | $32,118,000 | 23.31% |
| HARVARD MANAGEMENT CO INC | 3,464,990 | $138,080,000 | 12.96% |
| Brown University | 621,759 | $24,777,000 | 6.04% |
| Overbrook Management Corp | 729,125 | $29,056,000 | 5.86% |
| Bleichroeder LP | 824,033 | $32,838,000 | 5.13% |
| Geo Capital Gestora de Recursos Ltd | 200,692 | $7,998,000 | 3.81% |
| Lagoda Investment Management, L.P. | 140,435 | $5,596,000 | 2.65% |